Study: NCT01750879

Adverse event: Suicidal Ideation, unrelated
Serious: yes
Organ System: Psychiatric disorders
Frequency: 1 affected / 30 at risk

Adverse event: Anaphylactic reaction
Serious: no
Organ System: Immune system disorders
Notes: Build up AEs; Moderate to severe AEs reported
Frequency: 5 affected / 30 at risk

Adverse event: Abdominal pain
Serious: no
Organ System: Gastrointestinal disorders
Notes: Build up AEs; Moderate to severe AEs reported
Frequency: 1 affected / 30 at risk

Adverse event: Nausea/Vomting
Serious: no
Organ System: Gastrointestinal disorders
Notes: Build up AEs; Moderate to severe AEs reported
Frequency: 1 affected / 30 at risk

Adverse event: Urticaria
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Notes: At home AEs; Moderate to severe AEs reported
Frequency: 1 affected / 30 at risk

Adverse event: Anaphylactic reaction
Serious: no
Organ System: Immune system disorders
Notes: At home AEs; Moderate to severe AEs reported
Frequency: 15 affected / 30 at risk

Adverse event: Abdominal pain
Serious: no
Organ System: Gastrointestinal disorders
Notes: At home AEs; Moderate to severe AEs reported
Frequency: 4 affected / 30 at risk

Adverse event: Nausea/Vomiting
Serious: no
Organ System: Gastrointestinal disorders
Notes: At home AEs; Moderate to severe AEs reported
Frequency: 1 affected / 30 at risk

Adverse event: Asthma Exacerbation
Serious: no
Organ System: Respiratory, thoracic and mediastinal disorders
Notes: At home AEs; Moderate to severe AEs reported
Frequency: 1 affected / 30 at risk

Adverse event: Skin/oral pruritis
Serious: no
Organ System: Immune system disorders
Notes: DBPCFC2 AEs; 20 subjects on peanut; 9 subjects on placebo
Frequency: 1 affected / 20 at risk

Adverse event: Angiodema
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Notes: DBPCFC2 AEs; 20 subjects on peanut; 9 subjects on placebo
Frequency: 1 affected / 20 at risk

Adverse event: Anaphylactic reaction
Serious: no
Organ System: Immune system disorders
Notes: DBPCFC2 AEs; 20 subjects on peanut; 9 subjects on placebo
Frequency: 7 affected / 20 at risk

Adverse event: Reflux
Serious: no
Organ System: Gastrointestinal disorders
Notes: DBPCFC2 AEs; 20 subjects on peanut; 9 subjects on placebo
Frequency: 1 affected / 20 at risk

Adverse event: Abdominal pain
Serious: no
Organ System: Gastrointestinal disorders
Notes: DBPCFC2 AEs; 20 subjects on peanut; 9 subjects on placebo
Frequency: 1 affected / 20 at risk

Adverse event: Anaphylactic reaction
Serious: no
Organ System: Immune system disorders
Notes: Build up AEs; Moderate to severe AEs reported
Frequency: 1 affected / 11 at risk

Adverse event: Skin/oral pruritis
Serious: no
Organ System: Immune system disorders
Notes: DBPCFC2 AEs; 20 subjects on peanut; 9 subjects on placebo
Frequency: 2 affected / 9 at risk

Adverse event: Anaphylactic reaction
Serious: no
Organ System: Immune system disorders
Notes: DBPCFC2 AEs; 20 subjects on peanut; 9 subjects on placebo
Frequency: 7 affected / 9 at risk

Adverse event: Abdominal pain
Serious: no
Organ System: Gastrointestinal disorders
Notes: DBPCFC2 AEs; 20 subjects on peanut; 9 subjects on placebo
Frequency: 1 affected / 9 at risk

Adverse event: Nausea/Vomiting
Serious: no
Organ System: Gastrointestinal disorders
Notes: DBPCFC2 AEs; 20 subjects on peanut; 9 subjects on placebo
Frequency: 1 affected / 9 at risk

Adverse event: Other
Serious: no
Organ System: Gastrointestinal disorders
Notes: DBPCFC2 AEs; 20 subjects on peanut; 9 subjects on placebo
Frequency: 1 affected / 9 at risk

Adverse event: Wheeze/SOB
Serious: no
Organ System: Respiratory, thoracic and mediastinal disorders
Notes: DBPCFC2 AEs; 20 subjects on peanut; 9 subjects on placebo
Frequency: 1 affected / 9 at risk